09 January 2019 | News
WuXi Biologics will receive upfront, milestone payments and royalties.
image credit- pharmaceutical-journal.com
CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, and WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, jointly announced an expansion of their rare disease partnership to enable CANbridge to discover, develop and commercialize four additional drug candidates.
These new candidates target rare genetic chronic diseases. According to the agreement, CANbridge has an exclusive regional or global rights for these therapies. WuXi Biologics will receive upfront, milestone payments and royalties. WuXi Biologics will also be the exclusive clinical supplier and primary commercial supplier for all these programs.
“With this expansion of our partnership with WuXi Biologics, CANbridge continues to broaden our presence in rare disease, with a goal of bringing to the market treatments that are developed in China,” said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceuticals Inc.